Retatrutide
5 mg
Triple Agonist (GLP-1/GIP/Glucagon)
Retatrutide
Triple incretin agonist for advanced metabolic pathway research.
Prices in AUD. Tax included.
Research Use Only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Description
Retatrutide is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents the next generation of incretin-based research compounds. Early research suggests a broader metabolic impact than dual or single agonists.
Specifications
- SKU
- RETA-5MG
- Size
- 5 mg
- Form
- Lyophilised Powder
- Purity
- >99%
- Storage
- -20°C (lyophilised), 2-8°C (reconstituted)
- Shipping
- Australia Post — 3–5 business days
Research Summary
Preclinical research demonstrates that triple agonism produces additive effects on energy expenditure via glucagon receptor activation alongside the appetite-modulating effects of GLP-1 and GIP signaling. Phase 2 clinical trial data suggests dose-dependent body weight changes of significant magnitude.
Testing Protocol
- HPLC Purity Analysis
- Mass Spectrometry Identity Verification
- Endotoxin Screening (LAL Test)